Biopharmas raising money in public or private financings.

Med-tech firms raising money in public or private financings.

Biopharmas raising money in public or private financings.

Med-tech firms raising money in public or private financings.

HONG KONG – South Korea's biopharmaceutical venture Genome & Co. Ltd. recently secured KRW30.2 billion (US$25.2 million) in series C investment with an IPO and global clinical trial plans for next year.

Biopharmas raising money in public or private financings.

Med-tech firms raising money in public or private financings.

Biopharmas raising money in public or private financings.

BEIJING – Cancer and autoimmune specialist Innocare Pharma Ltd., of Beijing, is seeking a pre-revenue listing on the Hong Kong Stock Exchange (HKEX) to raise capital to advance its BTK inhibitor, ICP-022, to an NDA filing in China by the end of this year.

CEO Christine Bunt of Verseau Therapeutics Inc. told BioWorld that the company has prepared a "wave" of prospects from its macrophage checkpoint modulator (MCM) platform ready to crash upon the shores of cancer therapy, with 23 novel targets in the hopper.